

**CARDIOLOGY UPDATE 2006**

# The Role of Mast Cells in Acute Coronary Syndromes

Theoharis C. Theoharides, Ph.D., M.D.

Departments of <sup>1</sup>Pharmacology and Experimental Therapeutics, <sup>2</sup>Biochemistry, <sup>3</sup>Internal Medicine, Tufts University School of Medicine and Tufts – New England Medical Center, Boston, MA, USA

**ABBREVIATIONS:**

CAD: coronary artery disease;  
CRH: corticotropin releasing hormone;  
IL-6: interleukin 6;  
IR: ischemia reperfusion;  
LCA: left coronary artery;  
MI: myocardial infarction;  
VEGF: vascular endothelial growth factor

**KEY WORDS:** *inflammation, mast cells, stress, vascular permeability*

**ABSTRACT**

**OBJECTIVE:** Review evidence supporting the role of mast cells in cardiovascular pathophysiology. **BACKGROUND:** Cardiovascular inflammation has emerged as a key pathogenetic factor in coronary artery disease (CAD) and myocardial ischemia reperfusion (IR) injury. IR complicates all forms of coronary artery revascularization. Cardiac mast cells have been implicated in CAD, IR and myocardial infarction (MI) through the release of pro-arrhythmogenic and inflammatory mediators, especially interleukin-6 (IL-6), considered an independent risk factor. **METHODS:** We reviewed relevant literature and summarized our own findings. **RESULTS:** We showed that CAD is associated with high intracoronary release of IL-6. Acute stress triggers mast cell-dependent release of histamine and IL-6. Moreover, acute stress in ApoE <sup>-/-</sup> mice leads to ischemia. Mast cells express corticotropin-releasing-hormone (CRH) receptors, activation of which leads to selective release of vascular endothelial growth factor (VEGF), an isoform of which is vasodilatory. In a randomized prospective study, we investigated serum IL-6 levels and cardiac tissue susceptibility in the mast cell deficient (W/Wv) mice (n=12) and their normal littermates (+/+). When the left coronary artery (LCA) was ligated followed by 6 hr of reperfusion IL-6 levels increased significantly after reperfusion only in the +/+ mice, but not in mast cell deficient W/Wv mice; cardiac muscle viability was significantly higher in W/Wv than the +/+ mice. **CONCLUSION:** These results support targeting selective inhibition of cardiac mast cell activation as prophylactic therapy in clinical situations involving myocardial inflammation and/or revascularization.

**1. SELECTIVE RELEASE OF MAST CELL MEDIATORS**

Mast cells derive from a distinct precursor in the bone marrow [1] and mature under local tissue microenvironmental factors [2]. Mast cells are necessary for the development of allergic reactions, through crosslinking of their surface receptors for IgE (FcεRI), leading to degranulation and the release of vasoactive, pro-inflammatory and nociceptive mediators that include histamine, cytokines and proteolytic enzymes [3,4] (Table 1). The multitude of mediators that could be secreted, especially in response to many non-immunologic triggers (Table 2) has given rise to new speculations about the possible role of mast cells in immune responses, especially acquired immunity [5] and inflammation [6].

*Address for correspondence:*

T.C. Theoharides, Ph.D., M.D.  
Department of Pharmacology and Experimental Therapeutics,  
Tufts University School of Medicine,  
136 Harrison Avenue,  
Boston, MA 02111, USA  
Phone: (617) 636-6866  
Fax: (617) 636-2456  
E-mail: theoharis.theoharis@tufts.edu

Aspects of the work discussed were supported in part by grants from US NIH #AR47652 and Theta Biomedical Consulting and Development Co., Inc. (Brookline, MA) TCT has been awarded US patents #5,250,529; #6,020,305; #5,648,350; #5,855,884; #5,821,259; #5,994,357; #6,624,148 covering the use of CRH and mast cell blockers in inflammatory diseases.

**TABLE 1.** Mast cell Triggers

Antigen + IgE
Anaphylatoxins
CRH
IL-1
Immunoglobulin – free light chains
LPS
NGF
NT
SCF
SP
Superantigens
Ucn
VIP
Viral DNA sequences

Unlike allergic reactions, mast cells are rarely seen to degranulate during autoimmune [7] or inflammatory processes [8]. Instead, mast cells can secrete mediators without overt degranulation [9], through differential or selective release [10], probably regulated by the action of distinct protein kinases on a unique phosphoprotein [11,12]. In such cases, mast cells undergo ultrastructural alterations of their electron dense granular core indicative of secretion, but without overt degranulation, a process that has been termed “activation” [13-15] “intragranular activation” [16] or “piecemeal” degranulation [17]. Selective release has been reported for a number of mediators [18-20], especially serotonin [10], eicosanoids [21-23] or IL-6 [24-27]. In fact, we showed that interleukin-1 (IL-1) can stimulate human mast cells to release IL-6 selectively without degranulation, through a unique process utilizing 40-80 nm vesicles unrelated to the secretory granules (800-1000 nm) [28]. We also recently showed that corticotropin releasing hormone (CRH) secreted under stress can stimulate human mast cells through specific CRH receptors to release vascular endothelial growth factor (VEGF) selectively [29].

These findings suggest that mast cells may also be involved in inflammatory diseases [6,30] that include migraines [31] and cardiovascular disease [32].


## 2. CARDIOVASCULAR INFLAMMATION

Increasing evidence implicates acute psychological stress and cardiac mast cells in cardiovascular pathology, especially unstable angina and silent myocardial ischemia (MI). MI occurring without angina on presentation now appears to be a sizable portion of the MI population [33-36]. Allergic angina and MI have also been reported [37]. Mast cells have also recently been implicated in coronary microembolization and cardiomyocyte apoptosis [38]. There is growing evidence

that cardiac mast cells [39] participate in the development of atherosclerosis, coronary inflammation and cardiac ischemia. Mast cells have been identified in coronary arteries during spasm [40], and accumulate in the shoulder region of human coronary atheromas, especially in association with plaque rupture [32,41,42]. The human mast cell proteolytic enzyme chymase has been shown to be the main cardiac source of converting enzyme generating the coronary constrictor angiotensin II [43]. Chymase can also promote cholesterol removal from HDL and deposition on foam cells [44-46]. Mast cells tryptase can induce wider spread inflammation through stimulation of protease-activated receptors (PAR) [47]. Tryptase is also a biomarker in patients with stable CAD [48]. Cardiac mast cell-derived histamine [49] can constrict the coronaries [50] and can sensitize nerve endings [51]; this action is rendered probable by the recent findings showing adventitial mast cells localized close to nerve endings in atherosclerotic coronary arteries [52].

Acute stress induced rat cardiac mast cells activation documented morphologically [53] It was later shown that acute stress induced histamine release from mouse heart [54], as well as serum histamine and IL-6 elevations [54,55]; these were greater in apolipoprotein E (ApoE) knockout mice that develop atherosclerosis, but were still entirely dependent on mast cells [54,55]. These findings are significant since serum IL-6 elevations in patients with acute MI were shown to derive primarily from the coronary sinus [56]. Both histamine [57] and IL-6 [58] are significant predictive risk factors of coronary events.

We also recently showed that ischemia reperfusion in mice



**FIGURE 1.** Schematic representation of the sequence of events that may lead to cardiac mast cell activation and neurogenic inflammation, leading to CAD.

TABLE 2. Mast Cell Mediators

Mediators	Main Pathophysiologic Effects
<b>Prestored</b>	
<b>Biogenic Amines</b>	
Histamine	Vasodilation, angiogenesis, mitogenesis, pain
5-Hydroxytryptamine (5-HT, serotonin)	Vasoconstriction, pain
<b>Chemokines</b>	
IL-8, MCP-1, MCP-3, MCP-4, RANTES	Chemoattraction and tissue infiltration of leukocytes
<b>Enzymes</b>	
Arylsulfatases	Lipid/proteoglycan hydrolysis
Carboxypeptidase A	Peptide processing
Chymase	Tissue damage, angiotensin II synthesis, cholesterol liberation
Kinogenases	Synthesis of vasodilatory kinins, pain
Phospholipases	Arachidonic acid generation
Tryptase	Tissue damage, activation of PAR, inflammation, pain
<b>Peptides</b>	
Corticotropin-releasing hormone (CRH)	Inflammation, vasodilation
Endorphins	Analgesia
Endothelin	Sepsis
Kinins (bradykinin)	Inflammation, pain, vasodilation
Somatostatin (SRIF)	Anti-inflammatory (?)
Substance P (SP)	Inflammation, pain
Vasoactive intestinal peptide (VIP)	Vasodilation
Urocortin	Inflammation, vasodilation
Vascular endothelial growth factor (VEGF)	Neovascularization, vasodilation
<b>Proteoglycans</b>	
Chondroitin sulfate	Cartilage synthesis, anti-inflammatory
Heparin	Angiogenesis, nerve growth factor stabilization
Hyaluronic acid	Connective tissue, nerve growth factor stabilization
<b>De novo synthesized</b>	
<b>Cytokines</b>	
Interleukins (IL)-1,2,3,4,5,6,9,10,13,16	Inflammation, leukocyte migration, pain
INF- $\gamma$ ; MIF; TNF- $\alpha$	Inflammation, leukocyte proliferation/activation
<b>Growth Factors</b>	
SCF, GM-CSF, b-FGF, NGF, VEGF	Growth of a variety of cells
<b>Phospholipid metabolites</b>	
Leukotriene B4 LTB4	Leukocyte chemotaxis
Leukotriene C4 (LTC4)	Vasoconstriction, pain
Platelet activating factor (PAF)	Platelet activation, vasodilation
Prostaglandin D2 (PGD2)	Bronchostriction, pain
Nitric oxide (NO)	Vasodilation

CRH= corticotropin-releasing hormone, TGF- $\beta$ = transforming growth factor- $\beta$ , CSF= colony stimulating factor, TNF- $\alpha$ = tumor necrosis factor- $\alpha$ , INF $\gamma$ = Interferon- $\gamma$ , SRIF= somatomedin release inhibitory factor, somatostatin, MIF= macrophage inflammatory factor, GM-CSF= granulocyte monocyte-colony stimulating factor, b-FGF= fibroblast growth factor, NGF= nerve growth factor, SCF= Stem cell factor, VEGF= vascular endothelial growth factor.

increased serum IL-6 and myocardial necrosis, but not in W/W<sup>v</sup> mast cell deficient mice [59]. Such results have prompted editorials implicating mast cells CAD and MI [60].

## CONCLUSION

In summary, the mast cell has emerged as a unique immune cell that could be activated by many non-immune pro-

cesses, including acute stress [61,62], and could participate in CAD and MI (Figure 1).

---

ACKNOWLEDGMENTS

---

We thank Ms. Jessica Christian for her word processing skills.

REFERENCES

1. Rodewald HR, Dessing M, Dvorak AM, Galli SJ. Identification of a committed precursor for the mast cell lineage. *Science* 1996; 271:818-822.
2. Galli SJ. New concepts about the mast cell. *N Engl J Med* 1993; 328:257-265.
3. Kobayashi H, Ishizuka T, Okayama Y. Human mast cells and basophils as sources of cytokines. *Clin Exp Allergy* 2000; 30: 1205-1212.
4. Galli SJ, Wedemeyer J, Tsai M. Analyzing the roles of mast cells and basophils in host defense and other biological responses. *Int J Hematol* 2002; 75:363-369.
5. Galli SJ, Kalesnikoff J, Grimbaldston MA, Piliponsky AM et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. *Annu Rev Immunol* 2005; 23:749-786.
6. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. *J Neuroimmunol* 2004; 146:1-12.
7. Benoist C, Mathis D. Mast cells in autoimmune disease. *Nature* 2002; 420:875-878.
8. Woolley DE. The mast cell in inflammatory arthritis. *N Engl J Med* 2003; 348:1709-1711.
9. Theoharides TC, Douglas WW. Secretion in mast cells induced by calcium entrapped within phospholipid vesicles. *Science* 1978; 201:1143-1145.
10. Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. Differential release of serotonin and histamine from mast cells. *Nature* 1982; 297:229-231.
11. Theoharides TC, Sieghart W, Greengard P, Douglas WW. Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. *Science* 1980; 207:80-82.
12. Sieghart W, Theoharides TC, Alper SL, Douglas WW et al. Calcium-dependent protein phosphorylation during secretion by exocytosis in the mast cell. *Nature* 1978; 275:329-331.
13. Dimitriadou V, Lambrecht-Hall M, Reichler J, Theoharides TC. Histochemical and ultrastructural characteristics of rat brain perivascular mast cells stimulated with compound 48/80 and carbachol. *Neuroscience* 1990; 39:209-224.
14. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphologic changes reflecting secretion in rat dura mast cells. *Neuroscience* 1991; 44:97-112.
15. Theoharides TC, Sant GR, El-Mansoury M, Letourneau RJ et al. Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. *J Urol* 1995; 153:629-636.
16. Letourneau R, Pang X, Sant GR, Theoharides TC. Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis. *Br J Urol* 1996; 77:41-54.
17. Dvorak AM, McLeod RS, Onderdonk A, Monahan-Earley RA et al. Ultrastructural evidence for piecemeal and anaphylactic degranulation of human gut mucosal mast cells in vivo. *Int Arch Allergy Immunol* 1992; 99:74-83.
18. Kops SK, Van Loveren H, Rosenstein RW, Ptak W et al. Mast cell activation and vascular alterations in immediate hypersensitivity-like reactions induced by a T cell derived antigen-binding factor. *Lab Invest* 1984; 50:421-434.
19. Van Loveren H, Kops SK, Askenase PW. Different mechanisms of release of vasoactive amines by mast cells occur in T cell-dependent compared to IgE-dependent cutaneous hypersensitivity responses. *Eur J Immunol* 1984; 14:40-47.
20. Kops SK, Theoharides TC, Cronin CT, Kashgarian MG et al. Ultrastructural characteristics of rat peritoneal mast cells undergoing differential release of serotonin without histamine and without degranulation. *Cell Tissue Res* 1990; 262:415-424.
21. Benyon R, Robinson C, Church MK. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. *Br J Pharmacol* 1989; 97:898-904.
22. Levi-Schaffer F, Shalit M. Differential release of histamine and prostaglandin D2 in rat peritoneal mast cells activated with peptides. *Int Arch Allergy Appl Immunol* 1989; 90:352-357.
23. van Haaster CM, Engels W, Lemmens PJMR, Hornstra G et al. Differential release of histamine and prostaglandin D2 in rat peritoneal mast cells; roles of cytosolic calcium and protein tyrosine kinases. *Biochim Biophys Acta* 1995; 1265:79-88.
24. Leal-Berumen I, Conlon P, Marshall JS. IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. *J Immunol* 1994; 152:5468-5476.
25. Marquardt DL, Alongi JL, Walker LL. The phosphatidylinositol 3-kinase inhibitor wortmannin blocks mast cell exocytosis but not IL-6 production. *J Immunol* 1996; 156:1942-1945.
26. Gagari E, Tsai M, Lantz CS, Fox LG et al. Differential release of mast cell interleukin-6 via c-kit. *Blood* 1997; 89:2654-2663.
27. Hojo H, Sun R, Ono Y, Shishido T et al. Differential production of interleukin-6 and its close relation to liver metastasis in clones from murine P815 mastocytoma. *Cancer Let* 1996; 108: 55-59.
28. Kandere-Grzybowska K, Letourneau R, Boucher W, Bery J et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. *J Immunol* 2003; 171:4830-4836.
29. Cao J, Papadopoulou N, Kempuraj D, Boucher WS et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. *J Immunol* 2005; 174:7665-7675.
30. Theoharides TC. Mast cell: a neuroimmunoendocrine master player. *Int J Tissue React* 1996; 18:1-21.

31. Theoharides TC. Mast cells and migraines. *Perspect Biol Med* 1983; 26:672-675.
32. Constantinides P. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. *Circulation* 1995; 92:1083-1088.
33. Deedwania PC. Mental stress, pain perception and risk of silent ischemia. *JACC* 1995; 25:1504-1506.
34. Freeman LJ, Nixon PGF, Sallabank P, Reaveley D. Psychological stress and silent myocardial ischemia. *Am Heart J* 1987; 114: 477-482.
35. Deanfield JE, Shea M, Kensett M, Horlock P et al. Silent myocardial ischaemia due to mental stress. *Lancet* 1984; 2:1001-1005.
36. Rozanski A, Bairey CN, Krantz DS, Friedman J et al. Mental stress and the induction of silent myocardial ischemia in patients with coronary artery disease. *N Engl J Med* 1988; 318: 1005-1012.
37. Kounis NG, Zavras GM. Allergic angina and allergic myocardial infarction. *Circulation* 1996; 94:1789.
38. Zhang QY, Ge JB, Chen JZ, Zhu JH et al. Mast Cell Contributes to Cardiomyocyte Apoptosis after Coronary Microembolization. *J Histochem Cytochem* 2005.
39. Patella V, de Crescenzo G, Ciccarelli A, Marino I et al. Human heart mast cells: a definitive case of mast cell heterogeneity. *Int Arch Allergy Immunol* 1995; 106:386-393.
40. Forman MB, Oates JA, Robertson D, Robertson RM et al. Increased adventitial mast cells in a patient with coronary spasm. *N Engl J Med* 1985; 313:1138-1141.
41. Kaartinen M, Penttilä A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. *Circulation* 1994; 90:1669-1678.
42. Laine P, Kaartinen M, Penttilä A, Panula P et al. Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. *Circulation* 1999; 99: 361-369.
43. Jenne DE, Tschopp J. Angiotensin II-forming heart chymase is a mast-cell-specific enzyme. *Biochem J* 1991; 276:567.
44. Lee M, Kovanen PT, Tedeschi G, Oungre E et al. Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux. *J Lipid Res* 2003; 44:539-546.
45. Lee M, Metso J, Jauhiainen M, Kovanen PT. Degradation of phospholipid transfer protein (PLTP) and PLTP-generated pre-beta-high density lipoprotein by mast cell chymase impairs high affinity efflux of cholesterol from macrophage foam cells. *J Biol Chem* 2003; 278:13539-13545.
46. Lee M, Lindstedt LK, Kovanen PT. Mast cell-mediated inhibition of reverse cholesterol transport. *Arterioscler Thromb* 1992; 12:1329-1335.
47. Schmidlin F, Bunnett NW. Protease-activated receptors: how proteases signal to cells. *Curr Opin Pharmacol* 2001; 1:575-582.
48. Deliargyris EN, Upadhyya B, Sane DC, Dehmer GJ et al. Mast cell tryptase: a new biomarker in patients with stable coronary artery disease. *Atherosclerosis* 2005; 178:381-386.
49. Gristwood RW, Lincoln JC, Owen DA, Smith IR. Histamine release from human right atrium. *Br J Pharmacol* 1981; 74:7-9.
50. Genovese A, Spadaro G. Highlights in cardiovascular effects of histamine and H1-receptor antagonists. *Allergy* 1997; 52:67-78.
51. Christian EP, Udem BJ, Weinreich D. Endogenous histamine excites neurones in the guinea-pig superior cervical ganglion in vitro. *J Physiol* 1989; 409:297-312.
52. Laine P, Naukkarinen A, Heikkilä L, Penttilä A et al. Adventitial mast cells connect with sensory nerve fibers in atherosclerotic coronary arteries. *Circulation* 2000; 101:1665-1669.
53. Pang X, Alexacos N, Letourneau R, Seretakis D et al. A neurotensin receptor antagonist inhibits acute immobilization stress-induced cardiac mast cell degranulation, a corticotropin-releasing hormone-dependent process. *J Pharm & Exp Therap* 1998; 287:307-314.
54. Huang M, Berry J, Kandere K, Lytinas M et al. Mast cell deficient W/W(v) mice lack stress-induced increase in serum IL-6 levels, as well as in peripheral CRH and vascular permeability, a model of rheumatoid arthritis. *Int J Immunopath Pharmacol* 15, 249-254. 2002. Ref Type: Abstract
55. Huang M, Pang X, Karalis K, Theoharides TC. Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice. *Cardiovasc Res* 2003; 59:241-249.
56. Deliargyris EN, Raymond RJ, Theoharides TC, Boucher WS et al. Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failure. *Am J Cardiol* 2000; 86:913-918.
57. Clejan S, Japa S, Clemetson C, Hasabnis SS et al. Blood histamine is associated with coronary artery disease, cardiac events and severity of inflammation and atherosclerosis. *J Cell Mol Med* 2002; 6:583-592.
58. Suzuki M, Inaba S, Nagai T, Tatsuno H et al. Relation of C-reactive protein and interleukin-6 to culprit coronary artery plaque size in patients with acute myocardial infarction. *Am J Cardiol* 2003; 91:331-333.
59. Bhattacharya K, Farwell K, Huang M, Kempuraj D et al. Mast cell deficient W/Wv mice have lower serum IL-6 and less cardiac tissue necrosis than their normal littermates following myocardial ischemia-reperfusion. *Cardiovasc Res* 2006. Ref Type: In Press
60. Kounis NG. Kounis syndrome (allergic angina and allergic myocardial infarction): A natural paradigm? *Int J Cardiol* 2005.
61. Theoharides TC. Mast cells and stress - a psychoneuroimmunological perspective. *J Clin Psychopharmacol* 2002; 22: 103-108.
62. Theoharides TC, Donelan JM, Papadopoulou N, Cao J et al. Mast cells as targets of corticotropin-releasing factor and related peptides. *Trends Pharmacol Sci* 2004; 25:563-568.